BioNTech closed the third quarter of 2026 with EUR 1,289.2 million in revenue and a net profit of EUR 184.5 million, and it nudged up the midpoint of its full-year revenue guidance to a range of EUR 1.7 billion to EUR 1.9 billion. Those are the numbers management wants investors to focus on. A pair of less comfortable disclosures — one from inside the company, one from the deal table — suggest the market should look harder at how the restructuring behind those figures is being run.
A letter from the works council, and a site that stays shut
Handelsblatt reported on Tuesday on a letter from BioNTech’s works council to management, raising concerns about job insecurity, delayed decisions, and accounts of racism and threats during the company’s restructuring. The same newspaper reported on 15 October that BioNTech planned to close the former CureVac site in Tübingen despite an offer of up to EUR 20 million from an investor consortium. Citing documents and a confirmation from the works council, the paper said the company turned the bid down.
A site closure can make economic sense when the case for it clearly outweighs the alternatives. Rejecting a concrete offer, though, raises the bar on how that case gets explained. For shareholders, the test is whether management pairs firm decisions with responsible treatment of the workforce — and whether conflicts that surface during a reorganisation actually get addressed rather than deferred.
Roche takes the R&D bill from January 2027
On the cost side, BioNTech announced on Tuesday a change to how it shares expenses under its collaboration with Genentech/Roche. From 1 January 2027, future research and development costs for that programme will in principle be allocated to Roche/Genentech, while BioNTech retains the right to royalties if the programme succeeds. The arrangement ties a potential easing of the cost base to an economic stake that remains contingent on results.
That date now serves as a fixed marker for investors. So does the unchanged adjusted guidance for research and development as well as sales and administrative costs, which underscores that any relief should be judged programme by programme rather than as a blanket windfall.
A statistical win in breast cancer that the sponsors themselves call modest
The clinical record demands the same granular reading. Roughly two weeks ago, BioNTech and DualityBio reported that the Phase 3 DYNASTY-Breast02 study met its primary endpoint. The improvement in progression-free survival versus chemotherapy was statistically significant but moderate, and the overall survival data were still immature.
Should investors sell immediately? Or is it worth buying BioNTech?
What stands out is how restrained the partners were in framing it: they described the potential patient benefit as limited within the existing treatment landscape. They also reported a higher rate of interstitial lung disease than in earlier trials, including a small share of severe and fatal events. Efficacy and safety therefore have to be weighed together — that balance, more than the headline endpoint, determines how much weight the result deserves. The partners said they would discuss the data and decide on next steps.
Lung cancer data offer the counterweight
A separate programme provides the more encouraging read. Results from the Phase 2 ROSETTA Lung-107 study, also published about two weeks ago, tested pumitamig in combination with docetaxel in metastatic non-small cell lung cancer after first-line immunotherapy and chemotherapy. BioNTech and Bristol Myers Squibb reported a confirmed objective response rate of 36.7% across 30 patients evaluable for efficacy.
Set against the breast cancer update, the lung cancer figure shows why the pipeline has to be assessed one asset at a time. In a favourable scenario, medical progress in the development programmes and a lighter cost burden under the Genentech/Roche collaboration would reinforce each other. Whether that scenario holds depends on development candidates turning into therapies that actually work.
Nine months, one loss, and the question that outlasts the quarter
The broader financial picture is more mixed than a single quarter suggests. Alongside the EUR 184.5 million net profit for the third quarter of 2026, BioNTech posted a net loss of EUR 1,168.2 million across the first nine months of the year. If clinical limitations end up weighing on individual programmes more than the new cost allocation relieves them, the bear case writes itself.
Taken together, the quarter supplies genuine financial arguments, and the raised revenue range gives management a higher bar to clear. The internal criticism deserves a fixed place in any investment case alongside those numbers. The company’s story becomes more convincing if management brings the same clarity to staffing and site decisions that it showed in its cautious reading of the clinical data — and if the works council’s questions get answered rather than postponed.
Ad
BioNTech Stock: Buy or Sell?! New BioNTech Analysis from November 6 delivers the answer:
The latest BioNTech figures speak for themselves: Urgent action needed for BioNTech investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from November 6.
BioNTech: Buy or sell? Read more here...
